High-dose BU has become a mainstay in conditioning regimens for hematopoietic SCT (HSCT), despite its narrow therapeutic window and high toxicity. BU areas under the concentration time curves (AUC) higher than 1500 mM min are associated with increased risk of liver sinusoidal obstruction syndrome (SOS), 1 which still contributes to significant treatment-related morbidity and mortality. Therapeutic and toxic responses to BU are largely unpredictable, and occur in patients receiving identical treatment schedules. An AUC of 900-1500 mM min has been defined as the target exposure range in adults, 1 and controlling patient AUC by therapeutic drug monitoring (TDM) has become mandatory in many transplant centers, especially with oral administration of BU.
2 Despite TDM, SOS still presents a serious challenge in HSCT, suggesting other predisposing factors to liver toxicity likely exist in patients who develop this complication.
BU, like many chemotherapeutic drugs associated with liver toxicity, is metabolized in the liver via conjugation of glutathione by members of the glutathione S transferase (GST) family of phase II detoxification enzymes. 3 Srivastava et al. 4 assessed the impact of polymorphisms in GST genes on the risk of SOS in patients with b-thalassemia major undergoing HSCT and concluded that the GSTM1-null genotype predisposes to SOS. We did not find this association in thalassemic children of Israeli descent. 5 An increasing body of evidence indicates that elevated levels of plasma homocysteine (hyperhomocysteinemia) are associated with various vascular diseases, including cerebral, coronary, peripheral artery and venous thrombosis, 6 whereas hypohomocysteinemia limits production of sulfate, taurine and glutathione, all involved in phase II liver detoxification. 7 Methylenetetrahydrofolate reductase (MTHFR) is one of the main regulatory enzymes involved in homocysteine metabolism. 6 The C677T gene polymorphism in MTHFR was shown to correlate with reduced MTHFR enzyme activity. Consequently, homozygotes for the variant allele were found to have significantly higher plasma homocysteine concentrations. There was no difference in total homocysteine concentration between heterozygotes and subjects not carrying the C677T variant allele. Nevertheless, other reports have shown little or no impact of MTHFR C677T on the risk of vascular disease. 6 A second polymorphism in MTHFR, A1298C, like C677T, results in decreased MTHFR activity. Goekkurt et al. 3 found an association between A1298C and SOS but not C677T, in patients treated with BU. In this referred study the majority of the included subjects suffered from CML.
In the current study, we recruited 62 adult AML patients, referred for HSCT. Myeloablative conditioning regimen was based on high-dose oral BU (16 mg/kg total dose) and i.v. CY (120 mg/kg total daily dose). Patients also received CYA and a short course of MTX for prophylaxis of GVHD. One patient also received TBI. None of the patients received prior getsuzumab treatment. Prophylaxis against SOS included low-dose sodium heparin (i.v. 100 U/Kg in continuous infusion) and oral ursodeoxycholic acid. Despite TDM and prophylaxis, nine patients developed SOS, diagnosed according to the McDonald criteria 8 (that is, modified Seattle criteria); namely, the occurrence of two of the following events within 30 days of transplantation: unexplained weight gain of 410% from baseline values due to fluid accumulation, jaundice, hepatomegaly or upper right quadrant pain of liver origin. Of these, eight patients matched the more stringent Baltimore criteria for SOS. SOS was not biopsy-proven. One patient with SOS developed multi organ failure (MOF). Treatment for SOS consisted of diuretics and one patient received defibrotide. No statistically significant demographic or pharmacokinetic differences were found between individuals who developed SOS and those who did not (Table 1) . Furthermore, BU AUC values were similar and within the recommended therapeutic range, as previously published. 9 Patient DNA samples, isolated from whole blood taken before HSCT, were genotyped for MTHFR C677T and A1298C (rs1801133 and rs1801131, respectively). Our results show that MTHFR C677T ancestral allele (C) and A1298C variant allele (C) were significant risk factors for SOS (Table 2) . MTHFR haplotype 677CC/1298CC appeared to be significantly associated with SOS. These results are in partial agreement with those published by Goekkurt et al., 3 possibly due to the fact that our cohort consisted of AML patients only, whereas the patients in Goekkurt's cohort were mainly affected by CML, which is an entirely different disease. 10 Somewhat counter-intuitively, a study on 377 Israelis of Jewish descent found that subjects with the MTHFR 677CC/1298CC haplotype had significantly lower total homocysteine concentrations compared with subjects with the ancestral non variant 677CC/1298AA haplotype, 6 thus leading to reduced production of glutathione, sulfate and taurine. As BU is eliminated via conjugation to glutathione, 3 reduced levels of homocysteine could impair the liver's ability to eliminate BU. The involvement of glutathione exhaustion in SOS is further suggested by findings that low constitutive levels of glutathione in liver cells in vitro, together with further glutathione exhaustion by cytotoxic drugs or radiation, contribute to SOS development.
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If this proposed model is proven accurate, it may suggest that MTHFR C677T/A1298C genotyping along with measurement of plasma homocysteine concentration could be of clinical utility when using high-dose BU for myeloablation. 
